Skip to main content
OpenTrials

Clinical trial condition

Respiratory Syncytial Virus Infections

Explore clinical trials studying Respiratory Syncytial Virus Infections. Study availability and eligibility vary by location and protocol.

248 public trials 23 recruiting studies
Refine in advanced search Browse all conditions

Respiratory Syncytial Virus Infections trial results

Completed

Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children

NCT01006629

Conditions
Bronchopulmonary Dysplasia, Cardiovascular Abnormalities, Cardiovascular Diseases, +25 more
Locations
  • Site Ref # / Investigator 22699 Ivanovo, Russia
  • Site Ref # / Investigator 22694 Kazan', Russia
  • Site Ref # / Investigator 24022 Moscow, Russia
  • Site Ref # / Investigator 15744 Moscow, Russia
View all 19 locations
View Trial Details
Completed

Retrospective Palivizumab Study in Children With Hemodynamically Significant Congenital Heart Disease

NCT01075178

Conditions
Arrhythmias, Cardiac, Cardiovascular Diseases, Death, +11 more
Locations
  • Site Reference ID/Investigator# 6263 Linz, Austria
  • Site Reference ID/Investigator# 7956 Vienna, Austria
  • Site Reference ID/Investigator# 9403 Vienna, Austria
  • Site Reference ID/Investigator# 17821 Brussels, Belgium
View all 37 locations
View Trial Details
Completed

Study to Evaluate the Incidence of Hospitalizations and Respiratory Tract Infections in Premature Infants

NCT00384462

Conditions
Female Urogenital Diseases and Pregnancy Complications, Infections, Mononegavirales Infections, +10 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Central Arkansas Pediatric Clinic, P.A. Benton, Arkansas, United States
  • The Children's Clinic of Jonesboro, P.A. Jonesboro, Arkansas, United States
  • Arkansas Children's Hospital Research Institute Little Rock, Arkansas, United States
View all 59 locations
View Trial Details
Completed

Open-Label, Dose-Escalation Study of 2 to 5 IM Doses of MEDI-524 at 3 mg/kg or 15 mg/kg; Children to be Followed for 90 Days After Their Last Dose of MEDI-524

NCT00192478

Conditions
Infections, Mononegavirales Infections, Paramyxoviridae Infections, +4 more
Locations
  • Hospital General de Niños "Ricardo Gutierrez" Buenos Aires, Argentina
  • Hospital Interzonal General de Agudos "Dr. Diego Paroissien Buenos Aires, Argentina
  • Hospital Clinico Pontificia Universidad Catolica de Chile Santiago, Chile
View Trial Details

Related conditions